


SUPPLEMENTAL TABLES AND FIGURES

Supplemental Table S1. Primary antibodies used for Western blots.


Antigen	Manufacturer	Catalog #
ER α	Cell Signaling Technology (CST)	8644
pER α S104/106	Abcam	ab75753
pER α S118	Abcam	ab32396
TGF β R1	CST	3712
TGF β R2	CST	3713 ¹
TGF β R2	CST	79424
pSMAD2	CST	3108
SMAD2	CST	5339
pSMAD3	CST	9520
SMAD3	CST	9523
SMAD4	CST	38454
pp38	CST	4511
p38	CST	8690
pERK1/2	CST	4370
ERK1/2	CST	4695
pJNK1/2	CST	4668
JNK1/2	CST	9252
pmTOR S2481	CST	2974
pmTOR S2448	CST	2971
mTOR	CST	2972
E-cadherin	Abcam	ab15148
Vimentin	CST	5741
β -actin	CST	4967

¹This antibody was used in Figure S1A.



Supplemental Figure S1. Expression of Smad4 in ER+ breast cancer cells.

Smad4 expression in MCF-7, T47D, and ZR-75-1 maintained in E₂-deplete media for four days prior to E₂ (10⁻⁸M) stimulation (23 hours), followed by 1 hour of TGFβ (5 ng/ml).



Supplemental Figure S2. ER+ BMET-derived cells maintain parental phenotype.

E-cadherin vs. vimentin expression in ER+ MCF-7, T47D, ZR-75-1, and/or MCF-7 BMET-derived cells (38-2M, 41-1M, 41-2M and/or 43-4M), as compared to ER- MDA-SA cells by Western blot analysis.